Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...
That scuppered Sanofi's plans for filing tolebrutinib in PPMS, and the FDA has now slammed the brakes on its efforts to get ...
Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...
Proving her illness created an illusion of wellness for columnist Ahna Crum, but a relapse after nine years showed her she ...
Sanofi (NASDAQ:SNY) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. Sanofi (NASDAQ:SNY) said on ...
Irish Examiner on MSN
Two new subtypes of MS found in 'exciting' breakthrough
Scientists uncovered biological strands using artificial intelligence and hope discovery will revolutionise treatment ...
Using artificial intelligence (AI), researchers looked at brain scans and tested for a blood marker for nerve cell injury and ...
Researchers say the more they find out, the more likely 'we will be able to find treatments that can stop disease progression ...
Scientists from UCL have used artificial intelligence to discover two new biological sub-types of multiple sclerosis ...
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis: Paris Friday, December 26, 2025, 13:00 Hrs [IST] The US Foo ...
Researchers say the more they find out, the more likely 'we will be able to find treatments that can stop disease progression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback